|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Luo D, Carter KA, Miranda D and Lovell JF:
Chemophototherapy: An emerging treatment option for solid tumors.
Adv Sci (Weinh). 4(1600106)2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shukuya T and Carbone DP: Predictive
markers for the efficacy of Anti-PD-1/PD-L1 antibodies in lung
cancer. J Thorac Oncol. 11:976–988. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Aguiar PN Jr, Santoro IL, Tadokoro H, de
Lima Lopes G, Filardi BA, Oliveira P, Mountzios G and de Mello RA:
The role of PD-L1 expression as a predictive biomarker in advanced
non-small-cell lung cancer: A network meta-analysis. Immunotherapy.
8:479–488. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chen DS, Irving BA and Hodi FS: Molecular
pathways: Next-generation immunotherapy-inhibiting programmed
death-ligand 1 and programmed death-1. Clin Cancer Res.
18:6580–6587. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhao T, Li C, Wu Y and Li B: Prognostic
value of PD-L1 expression in tumor infiltrating immune cells in
cancers: A meta-analysis. PLoS One. 12(e0176822)2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y,
Zhang Q, Zhang F, Liu H, Li T, et al: The clinicopathological and
prognostic significance of PD-L1 expression assessed by
immunohistochemistry in lung cancer: A meta-analysis of 50 studies
with 11,383 patients. Transl Lung Cancer Res. 8:429–449.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ,
Lu ZY, Fang YC, Chen XF and Liu GT: The prognostic value of PD-L1
expression for non-small cell lung cancer patients: A
meta-analysis. Eur J Surg Oncol. 41:450–456. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhang M, Li G and Wang Y and Wang Y, Zhao
S, Haihong P, Zhao H and Wang Y: PD-L1 expression in lung cancer
and its correlation with driver mutations: A meta-analysis. Sci
Rep. 7(10255)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Fehrenbacher L, Spira A, Ballinger M,
Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D,
Artal-Cortes A, Lewanski C, et al: Atezolizumab versus docetaxel
for patients with previously treated non-small-cell lung cancer
(POPLAR): A multicentre, open-label, phase 2 randomised controlled
trial. Lancet. 387:1837–1846. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gotzsche PC, Loannidis JPA, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate healthcare
interventions: Explanation and elaboration. BMJ.
339(b2700)2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rohatgi A: WebPlotDigitizer, https://automeris.io/WebPlotDigitizer.
Accessed November, 2020.
|
|
14
|
Yang CY, Lin MW, Chang YL, Wu CT and Yang
PC: Programmed cell death-ligand 1 expression is associated with a
favourable immune microenvironment and better overall survival in
stage I pulmonary squamous cell carcinoma. Eur J Cancer. 57:91–103.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Theelen WSME, Kuilman T, Schulze K, Zou W,
Krijgsman O, Peters DDGC, Cornelissen S, Monkhorst K, Sarma P,
Sumiyoshi T, et al: Absence of PD-L1 expression on tumor cells in
the context of an activated immune infiltrate may indicate impaired
IFNγ signaling in non-small cell lung cancer. PLoS One.
14(e0216864)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mignon S, Willard-Gallo K, Van den Eynden
G, Salgado R, Decoster L, Marien KM, Vansteenkiste JF, Teugels E
and De Grève J: The relationship between tumor-infiltrating
lymphocytes, PD-L1 expression, driver mutations and clinical
outcome parameters in non-small cell lung cancer adenocarcinoma in
patients with a limited to no smoking history. Pathol OncolRes.
26:1221–1228. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vallonthaiel AG, Malik PS, Singh V, Kumar
V, Kumar S, Sharma MC, Mathur S, Arava S, Guleria R and Jain D:
Clinicopathologic correlation of programmed death ligand-1
expression in non-small cell lung carcinomas: A report from India.
Ann Diagn Pathol. 31:56–61. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chen L, Cao MF, Zhang X, Dang WQ, Xiao JF,
Liu Q, Tan YH, Tan YY, Xu YY, Xu SL, et al: The landscape of immune
microenvironment in lung adenocarcinoma and squamous cell carcinoma
based on PD-L1 expression and tumor-infiltrating lymphocytes.
Cancer Med. 8:7207–7218. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Paulsen EE, Kilvaer TK, Khanehkenari MR,
Al-Saad S, Hald SM, Andersen S, Richardsen E, Ness N, Busund LT,
Bremnes RM and Donnem T: Assessing PDL-1 and PD-1 in non-small cell
lung cancer: A novel immunoscore approach. Clin Lung Cancer.
18:220–233.e8. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sumitomo R, Hirai T, Fujita M, Murakami H,
Otake Y and Huang CL: PD-L1 expression on tumor-infiltrating immune
cells is highly associated with M2 TAM and aggressive malignant
potential in patients with resected non-small cell lung cancer.
Lung Cancer. 136:136–144. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang H, Li Z, Dong B, Sun W, Yang X, Liu
R, Zhou L, Huang X, Jia L and Lin D: Prognostic significance of
PD-L1 expression and CD8+ T cell infiltration in
pulmonary neuroendocrine tumors. Diagn Pathol.
13(30)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kim HS, Lee JH, Nam SJ, Ock CY, Moon JW,
Yoo CW, Lee GK and Han JY: Association of PD-L1 expression with
tumor-infiltrating immune cells and mutation burden in high-grade
neuroendocrine carcinoma of the lung. J Thorac Oncol. 13:636–648.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bonanno L, Pavan A, Dieci MV, Di Liso E,
Schiavon M, Comacchio G, Attili I, Pasello AG, Calabrese F, Rea F,
et al: The role of immune microenvironment in small-cell lung
cancer: Distribution of PD-L1 expression and prognostic role of
FOXP3-positive tumour infiltrating lymphocytes. Eur J Cancer.
101:191–200. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Song P, Guo L, Li W, Zhang F, Ying J and
Gao S: Clinicopathologic correlation with expression of PD-L1 on
both tumor cells and tumor-infiltrating immune cells in patients
with non-small cell lung cancer. J Immunother. 42:23–28.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Huang W, Ran R, Shao B and Li H:
Prognostic and clinicopathological value of PD-L1 expression in
primary breast cancer: A meta-analysis. Breast Cancer Res Treat.
178:17–33. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wang BC, Zhang ZJ, Fu C and Wang C:
Efficacy and safety of anti-PD-1/PD-L1 agents vs. chemotherapy in
patients with gastric or gastroesophageal junction cancer: A
systematic review and meta-analysis. Medicine (Baltimore).
98(e18054)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Huang Y and Shen A: The prediction
potential of neutrophil-to-lymphocyte ratio for the therapeutic
outcomes of programmed death receptor-1/programmed death ligand 1
inhibitors in non-small cell lung cancer patients: A meta-analysis.
Medicine (Baltimore). 99(e21718)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang C, Yu X and Wang W: A meta-analysis
of efficacy and safety of antibodies targeting PD-1/PD-L1 in
treatment of advanced nonsmall cell lung cancer. Medicine
(Baltimore). 95(e5539)2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Li JH, Ma WJ, Wang GG, Jiang X, Chen X, Wu
L, Liu ZS, Zeng XT, Zhou FL and Yuan YF: Clinicopathologic
significance and prognostic value of programmed cell death ligand 1
(PD-L1) in patients with hepatocellular carcinoma: A meta-analysis.
Front Immunol. 9(2077)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kim Y, Wen X, Cho NY and Kang GH:
Intratumoral immune cells expressing PD-1/PD-L1 and their
prognostic implications in cancer: A meta-analysis. Int J Biol
Markers: May 1, 2018 (Epub ahead of print). doi:
10.1177/1724600818770941.
|
|
31
|
Dix Junqueira Pinto G, de Souza Viana L,
Scapulatempo Neto C and Vicente Serrano S: Evaluation of PD-L1
expression in tumor tissue of patients with lung carcinoma and
correlation with clinical and demographic data. J Immunol Res.
2016(9839685)2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Pezzuto A, Cappuzzo F, D'Arcangelo M,
Ciccozzi M, Navarini L, Guerrini S, Ricci A, D'Ascanio M and Carico
E: Prognostic value of p16 protein in patients with surgically
treated non-small cell lung cancer; Relationship with Ki-67 and
PD-L1. Anticancer Res. 40:983–990. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sun C, Zhang L, Zhang W, Liu Y, Chen B,
Zhao S, Li W, Wang L, Ye L, Jia K, et al: Expression of PD-1 and
PD-L1 on tumor-infiltrating lymphocytes predicts prognosis in
patients with small-cell lung cancer. Onco Targets Ther.
13:6475–6483. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kim HR, Ha SJ, Hong MH, Heo SJ, Koh WY,
Choi EC, Kim EK, Pyo KH, Jung I, Seo D, et al: PD-L1 expression on
immune cells, but not on tumor cells, is a favorable prognostic
factor for head and neck cancer patients. Sci Rep.
6(36956)2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ma J, Chi D, Wang Y, Yan Y, Zhao S, Liu H,
Jing J, Pu H and Zhang M: Prognostic value of PD-L1 expression in
resected lung adenocarcinoma and potential molecular mechanisms. J
Cancer. 9:3489–3499. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Cha YJ, Kim HR, Lee CY, Cho BC and Shim
HS: Clinicopathological and prognostic significance of programmed
cell death ligand-1 expression in lung adenocarcinoma and its
relationship with p53 status. Lung cancer. 97:73–80.
2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chen S, Crabill GA, Pritchard TS, McMiller
TL, Wei P, Pardoll DM, Pan F and Topalian SL: Mechanisms regulating
PD-L1 expression on tumor and immune cells. J Immunother Cancer.
7(305)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wei Y, Zhao Q, Gao Z, Lao XM, Lin WM, Chen
DP, Mu M, Huang CX, Liu ZY, Li B, et al: The local immune landscape
determines tumor PD-L1 heterogeneity and sensitivity to therapy. J
Clin Invest. 129:3347–3360. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Mahoney KM, Sun H, Liao X, Hua P, Callea
M, Greenfield EA, Hodi FS, Sharpe AH, Signoretti S, Rodig SJ and
Freeman GJ: PD-L1 Antibodies to its cytoplasmic domain most clearly
delineate cell membranes in immunohistochemical staining of tumor
cells. Cancer Immunol Res. 3:1308–1315. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Mino-Kenudson M: Programmed cell death
ligand-1 (PD-L1) expression by immunohistochemistry: Could it be
predictive and/or prognostic in non-small cell lung cancer? Cancer
Biol Med. 13:157–170. 2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kintsler S, Cassataro MA, Drosch M,
Holenya P, Knuechel R and Braunschweig T: Expression of programmed
death ligand (PD-L1) in different tumors. Comparison of several
current available antibody clones and antibody profiling. Ann Diagn
Pathol. 41:24–37. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wu Y, Chen W, Xu ZP and Gu W: PD-L1
distribution and perspective for cancer immunotherapy-blockade,
knockdown, or inhibition. Front Immunol. 10(2022)2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Abdel-Rahman O: Correlation between PD-L1
expression and outcome of NSCLC patients treated with
anti-PD-1/PD-L1 agents: A meta-analysis. Crit Rev Oncol Hematol.
101:75–85. 2016.PubMed/NCBI View Article : Google Scholar
|
